Saxenda introduced GLP-1 weight-loss therapy to mainstream obesity medicine, but Wegovy dramatically changed expectations with stronger appetite suppression, weekly dosing, and substantially greater weight-loss results. Here’s why semaglutide overtook liraglutide in modern obesity treatment.
Saxenda and Wegovy both belong to the GLP-1 drug class, but their differences in dosing, effectiveness, and appetite control may significantly influence long-term weight-loss habits. Here’s how semaglutide and liraglutide compare in real-world obesity management.
GLP-1 microdosing offers a gradual, sustainable approach to weight loss and metabolic health. By using lower doses of medications like semaglutide, patients can manage appetite and insulin resistance while minimizing common side effects.